CYTK Share Price Performance
US$61.60
20.38 (49.44%)
22.6% undervalued intrinsic discount
US$79.56
Fair Value
Price US$61.60
AnalystConsensusTarget US$79.56
AnalystHighTarget US$123.09
AnalystLowTarget US$67.00
Fair ValueUS$79.56
Share Pricen/a
Cytokinetics, Incorporated Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
CYTK Community Narratives
AN
Fair Value
·Fair Value US$79.56 22.6% undervalued intrinsic discount
CYTK: Strong Cardiology Data Will Drive Momentum Ahead Of December 2025 FDA Decision
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value
·Fair Value US$123.09 50.0% undervalued intrinsic discount
Aging Global Population Will Boost HCM Therapy Uptake
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$67 8.1% undervalued intrinsic discount
Regulatory Delays Will Curb Uptake But Will Allow Cautious Progress
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regulatory Delays Will Curb Uptake But Will Allow Cautious Progress
Key Takeaways Dependence on successful late-stage drug development faces headwinds from payer resistance, pricing pressures, and complex reimbursement landscapes across regions. High R&D spending, lack of marketed products, and ongoing need for capital raise risk continued operating losses and dilution for shareholders.Read more
AN
US$67
8.1% undervalued intrinsic discount
Fair Value
Profit Margin
14.75%
Future PE
115.51x
Price in 2029
US$82.95
Aging Global Population Will Boost HCM Therapy Uptake
Key Takeaways Positive clinical data and strong commercialization capabilities could enable rapid market expansion and category leadership in difficult-to-treat heart conditions. Growing unmet demand, robust late-stage pipeline, and industry M&A interest make the company well-positioned for strategic partnerships or acquisition.Read more
AN
US$123.09
50.0% undervalued intrinsic discount
Fair Value
Profit Margin
12.51%
Future PE
127.79x
Price in 2029
US$152.29
CYTK: Strong Cardiology Data Will Drive Momentum Ahead Of December 2025 FDA Decision
Key Takeaways Successful late-stage clinical trials, commercial readiness, and diversification in products position the company for strong growth and reduced dependence on a single therapy. Strategic capital management and global partnerships support expansion, mitigate risks, and enable significant investment in commercialization and ongoing innovation.Read more
AN
US$79.56
22.6% undervalued intrinsic discount
Fair Value
Profit Margin
16.03%
Future PE
107.01x
Price in 2028
US$97.87
Trending Discussion
Recently Updated Narratives
AN
CYTK: Future Returns Will Hinge On HCM Launch And ACACIA Trial Outcome
Fair Value: US$67 8.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CYTK: Upcoming ACACIA nHCM Readout Will Drive 2026 Repricing Potential
Fair Value: US$123.09 50.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CYTK: Momentum Will Build Ahead Of Late Cycle FDA Decision
Fair Value: US$79.56 22.6% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cytokinetics, Incorporated Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 05, 2026
- -6.32
- -372.55%
- -891.60%
- -198.9%
About CYTK
- Founded
- 1997
- Employees
- 673
- CEO
- WebsiteView website
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
